277 related articles for article (PubMed ID: 29404979)
1. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Curran WJ; Scott CB; Nelson JS; Weinstein AS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG; Powlis WD
Cancer; 1992 Dec; 70(12):2909-17. PubMed ID: 1451073
[TBL] [Abstract][Full Text] [Related]
4. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
7. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
8. Imaging response in malignant glioma, RTOG 90-06.
Lustig RA; Seiferheld W; Berkey B; Yung AW; Scarantino C; Movsas B; Jones CU; Simpson JR; Fishbach J; Curran WJ
Am J Clin Oncol; 2007 Feb; 30(1):32-7. PubMed ID: 17278892
[TBL] [Abstract][Full Text] [Related]
9. Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Shibamoto Y
Am J Clin Oncol; 1995 Oct; 18(5):449-53. PubMed ID: 7572767
[TBL] [Abstract][Full Text] [Related]
10. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
11. [Hyperfractionated radiotherapy and adjuvant chemotherapy in patients with malignant gliomas].
Jeremić V; Grujicić D; Samarcić M; Antunović V; Joksimović M; Milicić B; Rasulić L; Nikolić N
Srp Arh Celok Lek; 1997; 125(11-12):333-9. PubMed ID: 9480566
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
[TBL] [Abstract][Full Text] [Related]
13. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Corn BW; Yousem DM; Scott CB; Rotman M; Asbell SO; Nelson DF; Martin L; Curran WJ
Cancer; 1994 Nov; 74(10):2828-35. PubMed ID: 7954244
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
16. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
18. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
[TBL] [Abstract][Full Text] [Related]
19. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Brem H; Ewend MG; Piantadosi S; Greenhoot J; Burger PC; Sisti M
J Neurooncol; 1995 Nov; 26(2):111-23. PubMed ID: 8787853
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Jenkinson MD; Smith TS; Haylock B; Husband D; Shenoy A; Vinjamuri S; Walker C; Pietronigro D; Warnke PC
J Neurooncol; 2010 Aug; 99(1):103-13. PubMed ID: 20063175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
